Although the various subtypes of breast cancer affect many thousands of women worldwide each year, information and knowledge about the cost of illness and labour productivity of patients with HER2-positive early-stage and metastatic breast cancer treated with trastuzumab is limited. The gene discussed is ERBB2; the disease is breast cancer.